Clearside Biomedical, Inc.
CLSD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $201 | $492 | $2,330 | $306 |
| % Growth | -59.1% | -78.9% | 661.4% | – |
| Cost of Goods Sold | $0 | $84 | $248 | $149 |
| Gross Profit | $201 | $408 | $2,082 | $157 |
| % Margin | 100% | 82.9% | 89.4% | 51.3% |
| R&D Expenses | $2,933 | $1,584 | $4,463 | $4,244 |
| G&A Expenses | $4,308 | $2,476 | $2,824 | $3,062 |
| SG&A Expenses | $4,308 | $2,476 | $2,824 | $3,062 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$84 | $0 | $0 |
| Operating Expenses | $7,241 | $3,976 | $7,287 | $7,306 |
| Operating Income | -$7,040 | -$3,568 | -$5,205 | -$7,149 |
| % Margin | -3,502.5% | -725.2% | -223.4% | -2,336.3% |
| Other Income/Exp. Net | $1,068 | -$927 | -$2,303 | -$157 |
| Pre-Tax Income | -$5,972 | -$4,495 | -$7,508 | -$7,306 |
| Tax Expense | $0 | $0 | $715 | $0 |
| Net Income | -$5,972 | -$4,495 | -$8,223 | -$7,306 |
| % Margin | -2,971.1% | -913.6% | -352.9% | -2,387.6% |
| EPS | -1.14 | -0.87 | -1.65 | -1.445 |
| % Growth | -31% | 47.3% | -14.2% | – |
| EPS Diluted | -1.14 | -0.87 | -1.65 | -1.445 |
| Weighted Avg Shares Out | 5,234 | 5,190 | 5,128 | 5,057 |
| Weighted Avg Shares Out Dil | 5,234 | 5,190 | 5,128 | 5,057 |
| Supplemental Information | – | – | – | – |
| Interest Income | $65 | $115 | $163 | $358 |
| Interest Expense | $2,570 | $2,762 | $2,673 | $2,579 |
| Depreciation & Amortization | $84 | $84 | $85 | $79 |
| EBITDA | -$3,318 | -$1,649 | -$4,750 | -$4,648 |
| % Margin | -1,650.7% | -335.2% | -203.9% | -1,519% |